Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Nov 28;12(1):20495.
doi: 10.1038/s41598-022-23319-1.

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours

Yoon-Jung Kang  1 , Sophie O'Haire  2   3 , Fanny Franchini  2   3 , Maarten IJzerman  2   3 , John Zalcberg  4 , Finlay Macrae  5 , Karen Canfell  1 , Julia Steinberg  6
Affiliations
Meta-Analysis

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours

Yoon-Jung Kang et al. Sci Rep. .

Abstract

Immune checkpoint inhibitors have been approved in the USA for tumours exhibiting mismatch repair deficiency (dMMR), microsatellite instability (MSI), or high tumour mutational burden (TMB), with regulatory and reimbursement applications in multiple other countries underway. As the estimated budget impacts of future reimbursements depend on the size of the potential target population, we performed a scoping review and meta-analysis of the prevalence of these pan-tumour biomarkers in different cancers. We systematically searched Medline/Embase and included studies reporting the prevalence of dMMR/MSI/high TMB in solid tumours published 01/01/2018-31/01/2021. Meta-analyses were performed separately for the pan-cancer prevalence of each biomarker, and by cancer type and stage where possible. The searches identified 3890 papers, with 433 prevalence estimates for 32 different cancer types from 201 studies included in meta-analyses. The pooled overall prevalence of dMMR, MSI and high TMB (≥ 10 mutations/Mb) in pan-cancer studies was 2.9%, 2.7% and 14.0%, respectively. The prevalence profiles of dMMR/MSI and high TMB differed across cancer types. For example, endometrial, colorectal, small bowel and gastric cancers showed high prevalence of both dMMR and MSI (range: 8.7-26.8% and 8.5-21.9%, respectively) and high TMB (range: 8.5-43.0%), while cervical, esophageal, bladder/urothelial, lung and skin cancers showed low prevalence of dMMR and MSI (< 5%), but high prevalence of high TMB (range: 23.7-52.6%). For other cancer types, prevalence of all three biomarkers was generally low (< 5%). This structured review of dMMR/MSI/high TMB prevalence across cancers and for specific cancer types and stages provide timely evidence to inform budget impact forecasts in health technology assessments for drug approvals based on these pan-tumour biomarkers.

PubMed Disclaimer

Conflict of interest statement

Professor Karen Canfell is co–principle investigator of an investigator-initiated trial of cervical screening, “Compass”, run by The Australian Centre for the Prevention of Cervical Cancer (ACPCC), which is a government-funded not-for-profit charity; “Compass” receives infrastructure support from the Australian government and the ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics, USA. She is also co–principle investigator on a major implementation program Elimination of Cervical Cancer in the Western Pacific which has received support from the Minderoo Foundation and the Frazer Family Foundation, and equipment donations from Cepheid Inc. She also receives support for a range of other Australian and international government projects including support from philanthropic organizations, WHO, and government agencies related to cervical cancer control. K.C. is a Chair or member of a number of government or meetings convened by the World Health Organization (WHO), or philanthropic organizations such as Bill and Melinda Gates Foundation (BMGF). Professor John Zalcberg has stock and other ownership interests in Biomarin, Ophthea, Amarin, Concert Pharmaceuticals, Frequency Therapeutics, Gilead, Madrigal Pharmaceuticals, UniQure, Zogenix, rphazyme, Moderna Therapeutics, TWST and Novavax. JZ holds a consulting or advisory role in Merck Serono, Targovax, Merck Sharp & Dohme, Halozyme, Lipotek, Specialized Therapeutics, CEND, Deciphera, REVOLUTION MEDICINE, FivePHusion, Genorbio, 1Global and Novotech. JZ’s institution received funding from Merck Serono, Bristol-Hyers Squibb, AstraZeneca, Pfizer, IQvia, Mylan, Ipsen, Elsai, Medtronic and MSD Oncology. JZ received travel, accommodations and expenses from Merck Serono, AstraZeneca, Merck Sharp & Dohme, Deciphera and Sanofi. Professor Finlay Macrae is a member of the Clinical Advisory Group of the National Bowel Cancer Screening Program. His group receives support from Cancer Australia and the Victorian Cancer Agency for Australian leadership of the CAPP trials for cancer prevention in Lynch Syndrome. He chairs the Australian and New Zealand Gastrointestinal International Training Association which receives support from industry, philanthropic organizations and Australian Government for its activities in the Indo-Pacific region. He is the principal investigator of several clinical trials funded by the pharmaceutical industry. Other authors do not have competing interest.

Figures

Figure 1
Figure 1
Scoping review process. aWe determined a minimum sample size threshold for each cancer type and stage to focus on estimates from larger studies where available, while retaining 10+ studies (see Supplementary Table S6 for details). bExcluding studies focused on selected populations based on family history or inherited predisposition to cancer, rare histologic subtype(s) only, or specific molecular subtypes only. cOther reasons for exclusion are unavailability of the full-text article (n = 10), focus on validation of a new assay (n = 8), use of blood rather than tumour samples (n = 8), and < 4 mismatch repair proteins evaluated by immunohistochemistry for colorectal cancer (n = 4).
Figure 2
Figure 2
Landscape of studies reporting the prevalence of dMMR/MSI/high TMB. (a) Number of studies by cancer stage; (b) the relative proportion of studies by cancer stage; (c) the relative proportion of studies by study sample size; (d) the relative proportion of studies by tumour group; (e) number of studies reporting the prevalence of dMMR/MSI; and (f) number of studies reporting the prevalence of high TMB. dMMR mismatch repair deficiency; MSI microsatellite instability; TMB tumour mutational burden.
See this image and copyright information in PMC

References

    1. Pestana RC, Sen S, Hobbs BP, Hong DS. Histology-agnostic drug development—Considering issues beyond the tissue. Nat. Rev. Clin. Oncol. 2020;17(9):555–568. doi: 10.1038/s41571-020-0384-0. - DOI - PubMed
    1. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site—When a biomarker defines the indication. N. Engl. J. Med. 2017;377(15):1409–1412. doi: 10.1056/NEJMp1709968. - DOI - PubMed
    1. U.S. Food & Drug Administration. FDA News release: FDA approves first cancer treatment for any solid tumor with a specific genetic feature. https://www.fda.gov/news-events/press-announcements/fda-approves-first-c.... Accessed 21 October 2020.
    1. Therapeutic Goods Administration. Prescription medicines: new or extended uses, or new combinations of registered medicines, 2019. https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-or-ne.... Accessed 21 October 2020.
    1. Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer. https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-k.... Accessed 23 December 2021.

Substances